---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000003"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-01-03T23:59:59+00:00"
generated_at: "2026-06-20T20:57:13.729945+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene Therapeutics EVP of R&D Rafael Amado resigns effective Dec 30, 2022

## Summary
- Rafael G. Amado, Executive Vice President of Research and Development, resigned.
- Effective date of resignation: December 30, 2022.
- Resignation is to pursue another opportunity; no replacement named.
- Departure of top R&D executive may impact pipeline development.

## SEC filing metadata
- accession: 0001737287-23-000003
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-01-03T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000003/0001737287-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000003/allo-20221227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000003
- JSON: https://secwatch.observer/filing/0001737287-23-000003.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000003.txt

## Key facts
- Executive change
  Rafael G. Amado resigned as Executive Vice President of Research and Development at Allogene Therapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President of Research and Development
  source text: On December 27, 2022, Rafael G. Amado, M.D., the Executive Vice President of Research and Development of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective December 30, 2022, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000003/0001737287-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.